Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 21865203)

Published in Heart on August 23, 2011

Authors

Mitul B Kadakia1, Caroline S Fox, Benjamin M Scirica, Sabina A Murphy, Marc P Bonaca, David A Morrow

Author Affiliations

1: Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19103, USA. kadakia@post.harvard.edu

Articles cited by this

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08

The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev (2007) 16.67

General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49

Abdominal obesity and metabolic syndrome. Nature (2006) 14.20

The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86

Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol (1994) 7.21

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol (2008) 5.19

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J (2007) 4.88

Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation (2007) 3.20

Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med (2010) 2.88

Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA (2007) 2.57

Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49

Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord (1993) 2.39

Hypothesis concerning the U-shaped relation between body mass index and mortality. Am J Epidemiol (1997) 2.15

Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation (2008) 2.02

The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J (2007) 1.85

The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol (2002) 1.31

The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. Am Heart J (2006) 1.26

Subcutaneous abdominal adipose tissue is associated with the metabolic syndrome in Asian Indians independent of intra-abdominal and total body fat. Heart (2010) 1.13

Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol (2007) 1.07

Regional distribution of muscle and fat mass in men--new insight into the risk of abdominal obesity using computed tomography. Int J Obes (1989) 1.07

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J (2006) 1.05

Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J (2006) 1.04

Adiposity and cardiovascular disease: are we using the right definition of obesity? Eur Heart J (2007) 1.01

Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher long-term risks including recurrent re-infarction and cardiac death. Int J Cardiol (2005) 1.01

Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol (2003) 0.99

Anthropometric assessment of abdominal obesity and coronary heart disease risk in men: the PRIME study. Heart (2009) 0.91

Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol (1996) 0.91

Association between anthropometric obesity measures and coronary artery disease: a cross-sectional survey of 16,657 subjects from 444 Polish cities. Heart (2009) 0.90

Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost (1999) 0.89

Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. Am J Med (2005) 0.87

Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol (2008) 0.85

Articles by these authors

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96

Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22

Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54

Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85

The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90

Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66

Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55

Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34

Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29

Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (2009) 6.19

Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11

Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89

New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58

Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47

Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33

Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation (2007) 5.10

The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02

Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81

Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet (2008) 4.71

Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48

A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31

Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation (2005) 4.08

Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07

Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92

The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78

Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 3.55

Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J (2009) 3.54

Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51

Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2006) 3.48

Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab (2010) 3.39

Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation (2006) 3.35

Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care (2008) 3.33

On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25

Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24

Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest (2011) 3.23

Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol (2005) 3.20

Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18

NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet (2009) 3.18

Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation (2005) 3.16

Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2008) 3.12

Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol (2010) 3.05

Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 2.93

Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J (2008) 2.92

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86

Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84

Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83

Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care (2009) 2.80

FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77

Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2010) 2.76

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75

Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA (2002) 2.75

Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73